Immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL)

Patent metadata

Field	Value
Publication number	US-10144763-B2
Application number	US-201815965212-A
Country	US
Kind code	B2
Filing date	Apr 27, 2018
Priority date	Jun 20, 2014
Publication date	Dec 4, 2018
Grant date	Dec 4, 2018

Abstract

The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.

First claim

The invention claimed is:

1. A method of eliciting an immune response in a patient who has cancer, comprising administering to said patient a population of activated T cells that selectively recognize cells, which present a peptide consisting of the amino acid sequence of SEQ ID NO: 1,
wherein the peptide is in a complex with an MHC molecule; and

wherein said cancer is selected from the group consisting of chronic lymphoid leukemia (CLL), acute myelogenous leukemia (AML), adrenal gland adrenal cortical adenoma, bone giant cell tumor of bone, bone non-ossifying fibroma, breast carcinoma, colon adenocarcinoma, non-Hodgkin's lymphoma, endometrium adenocarcinoma endometrioid, kidney angiomyolipoma, kidney carcinoma, kidney oncocytoma, liver focal nodular hyperplasia, liver hepatocellular carcinoma, lymph node Hodgkin's disease, lymph node papillary carcinoma of thyroid, medullary carcinoma of thyroid origin, metastatic adenocarcinoma of stomach, neurofibroma, ovary thecomafibroma, pancreas adenocarcinoma, pancreas microcystic adenoma, parathyroid gland adenoma, rectum adenocarcinoma, skin squamous cell carcinoma, spleen chronic myeloid leukemia, stomach gastrointestinal stromal tumor (GIST), thyroid gland nodular hyperplasia, thyroid gland papillary carcinoma, and uterine cervix squamous cell carcinoma.

2. The method of claim 1 , wherein the T cells are autologous to the patient.

3. The method of claim 1 , wherein the T cells are obtained from a healthy donor.

4. The method of claim 1 , wherein the T cells are obtained from tumor infiltrating lymphocytes or peripheral blood mononuclear cells.

5. The method of claim 1 , wherein the activated T cells are expanded in vitro.

6. The method of claim 1 , wherein the MHC molecule is a class I MHC molecule.

7. The method of claim 1 , wherein the antigen presenting cell is infected with a recombinant virus expressing the peptide.

8. The method of claim 7 , wherein the antigen presenting cell is a dendritic cell or a macrophage.

9. The method of claim 5 , wherein the expansion is in the presence of an anti-CD28 antibody and IL-12.

10. The method of claim 1 , wherein the activated T cells are cytotoxic T cells produced by contacting T cells with an antigen presenting cell that expresses the peptide in a complex with an MHC class I molecule on the surface of the antigen presenting cell, for a period of time sufficient to activate said T cell.

11. The method of claim 10 , wherein the contacting is in vitro.

12. The method of claim 1 , wherein the population of activated T cells are administered in the form of a composition.

13. The method of claim 12 , wherein the composition comprises an adjuvant.

14. The method of claim 13 , wherein the adjuvant is selected from the group consisting of imiquimod, resiguimod, GM-CSF, cyclophosphamide, Sunitinib, bevacizumab, interferon-alpha, CpG oligonucleotides and derivatives, poly-(I:C) and derivatives, RNA, sildenafil, and particulate formations with poly(lactid coglycolid) (PLG) and virosomes.

15. The method of claim 1 , wherein the immune response is capable of killing targeted cancer cells.

16. The method of claim 15 , wherein the immune response comprises a cytotoxic T cell response.

17. The method of claim 1 , wherein the cancer is chronic lymphoid leukemia (CLL).

18. The method of claim 1 , wherein the cancer is acute myelogenous leukemia (AML).

Assignees

• Immatics Biotechnologies Gmbh

Inventors

• Stickel Juliane
• Kowalewski Daniel Johannes
• Rammensee Hans-Georg
• Stevanovic Stefan

Classifications

• G01N33/575

  for cancer · CPC title

• G01N2333/70539

  MHC-molecules, e.g. HLA-molecules · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• G16B20/00

  ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations · CPC title

• C12Q2600/118

  Prognosis of disease development · CPC title